Adam Kinnaird, MD, PhD, FRCSC, presented “Utility of Micro-Ultrasound in Prostate Cancer Active Surveillance” during the 8th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer on October 8, 2024.
How to cite: Kinnaird, Adam. “Utility of Micro-Ultrasound in Prostate Cancer Active Surveillance.” October 8, 2024. Accessed Dec 2024. https://grandroundsinurology.com/utility-of-micro-ultrasound-in-prostate-cancer-active-surveillance/
Utility of Micro-Ultrasound in Prostate Cancer Active Surveillance – Summary
Adam Kinnaird, MD, PhD, FRCSC, discusses micro-ultrasound’s utility in active prostate cancer surveillance. In this 11-minute presentation, he outlines the evolution of prostate biopsy techniques and highlights micro-ultrasound’s ability to provide high-resolution imaging that detects prostate cancers invisible to conventional ultrasound. The Primus Scoring System, akin to the PI-RADS system for MRI, aids in classifying findings with promising accuracy in detecting clinically significant prostate cancer.
Dr. Kinnaird presents comparative studies showing micro-ultrasound as non-inferior to MRI in biopsy-naive patients. Preliminary data from trials reveal high concordance between micro-ultrasound and MRI. He highlights advancements in artificial intelligence, such as AI-driven heat maps for targeted biopsies, which show potential for improving diagnostic accuracy in both biopsy-naive and active surveillance settings.
The talk emphasizes the promise of micro-ultrasound in reducing overdiagnosis, improving patient outcomes, and potentially complementing or replacing MRI in specific clinical contexts.
The Global Summit on Precision Diagnosis and Treatment of Prostate Cancer is a unique multi-disciplinary forum organized to inform the key health care stakeholders about the emerging advances in clinical case and research and create a consensus-based vision for the future of precision care and educational and research strategy for its realization. The mission of the Summit is to fill the currently existing gap between the key experts of in vivo imaging, the world authorities in the in vitro fluid- and tissue-based molecular diagnostics, including genomics, and thought leaders in the development of novel observation strategies (e.g., active surveillance, or AS) and therapeutic interventions.
